A pluripotent stem cell-derived hepatoblast, its preparation method and application

By employing a four-stage induction culture medium scheme and utilizing specific growth factors and basal culture medium components, the differentiation efficiency and cell viability of pluripotent stem cells into hepatocytes were successfully improved. This solved the problems of low differentiation efficiency and high cost of hepatocytes in existing technologies, and enabled the preparation of high-purity hepatocytes.

CN123107913APending Publication Date: 2026-11-17WUHAN GANYI BIOMEDICAL TECHNOLOGY CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202611624284.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-10-20
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

In existing technologies, pluripotent stem cells suffer from insufficient cell viability and low differentiation efficiency during differentiation into hepatocytes, and the costs are high, making it difficult to achieve large-scale production.

Method used

A four-stage induction culture medium protocol was adopted, including the first induction medium, the second induction medium, the third induction medium and the fourth induction medium. Specific concentrations of growth factors such as activin A, CHIR99021, A8301, FGF2, BMP4, TTNPB and trichomoniasisin were used in combination with the components of the basal culture medium to gradually induce pluripotent stem cells to differentiate into hepatoblasts.

Benefits of technology

It improves the cell viability and differentiation efficiency of hepatoblasts, reduces production costs, ensures high expression and purity of hepatoblast markers, is suitable for clinical-grade cell therapy, and reduces production complexity and cost.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123107913A_ABST
    Figure CN123107913A_ABST
Patent Text Reader

Abstract

This invention discloses a pluripotent stem cell-derived hepatoblast cells, its preparation method, and its applications, relating to the fields of cell biology and regenerative medicine. The method includes the following steps: pluripotent stem cells are sequentially cultured in a first induction medium, a second induction medium, a third induction medium, and a fourth induction medium to obtain hepatoblast cells; the first induction medium includes basal medium, activin A, and a glycogen synthase kinase inhibitor; the second induction medium includes basal medium and activin A; the third induction medium includes basal medium, a TGF-β type I receptor inhibitor, an FGF signaling pathway activator, a BMP signaling pathway activator, and a retinoic acid activator; the fourth induction medium includes basal medium, activin A, a BMP signaling pathway activator, and a cAMP / PKA activator. This invention improves the cell viability and differentiation efficiency of hepatoblast cells while reducing culture costs.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the fields of cell biology and regenerative medicine, and in particular to a pluripotent stem cell-derived hepatoblast, its preparation method, and its applications. Background Technology

[0002] Cell therapy has provided new insights into liver disease treatment, with hepatocyte transplantation and bioartificial liver support systems showing promising promise in preclinical and clinical research. However, the implementation of these treatments faces a common bottleneck: a lack of sufficient, high-quality sources of functional hepatocytes. Primary hepatocytes are difficult to culture in vitro, have limited proliferative capacity, and are prone to loss of function; while liver cancer cell lines can proliferate indefinitely, they exhibit abnormal function and pose a tumorigenic risk. Pluripotent stem cells possess unlimited self-renewal and multi-directional differentiation potential, providing an ideal source of seed cells for hepatocyte preparation. Through in vitro directed differentiation, human pluripotent stem cells can differentiate into hepatocytes and mature hepatocyte-like cells. Hepatocytes, as important intermediate stage cells in liver development, possess bidirectional differentiation potential, capable of differentiating into hepatocytes and bile duct epithelial cells while retaining strong proliferative capacity.

[0003] Currently, insufficient cell viability and low differentiation efficiency are common problems in the induction of pluripotent stem cells into hepatocytes, and are also one of the core bottlenecks in cell quality. As a crucial intermediate stage in the differentiation of pluripotent stem cells into mature hepatocytes, even slight deviations in culture conditions and inducing factor regulation at each step can lead to decreased cell viability, manifesting as weak cell adhesion, increased apoptosis rate, insufficient proliferation, and even abnormal cell morphology (such as shrinkage and detachment), which can lead to induction failure in severe cases. For example, imbalance of inducing factors and cellular stress: Inducing hepatocytes requires precise regulation of the concentration and timing of growth factors such as BMP4, HGF, and dexamethasone. If the concentration of these factors is too high / too low, or if the timing of their addition is incorrect, it can disrupt the cell differentiation direction, trigger endoplasmic reticulum stress, and subsequently induce apoptosis, reducing cell viability. Furthermore, contamination by other cells during the induction process can occur. These contaminated cells compete with hepatocytes for nutrients, and the presence of undifferentiated pluripotent stem cells can interfere with the normal differentiation of hepatocytes, leading to insufficient target cell viability and limited proliferation. Meanwhile, existing induction culture medium protocols mostly rely on expensive B27, resulting in high production costs and making it difficult to achieve large-scale production. Summary of the Invention

[0004] In view of the shortcomings of the above-mentioned related technologies, the present invention provides a hepatoblast derived from pluripotent stem cells, its preparation method and application.

[0005] In a first aspect, the present invention provides a method for preparing hepatoblasts derived from pluripotent stem cells, which adopts the following technical solution: A method for preparing hepatoblasts derived from pluripotent stem cells includes the following steps: culturing pluripotent stem cells sequentially in a first induction medium, a second induction medium, a third induction medium, and a fourth induction medium to obtain hepatoblasts; The first induction medium includes basal medium, activin A at a working concentration of 80-150 ng / mL and CHIR99021 at a working concentration of 1-3 μM, and does not contain intracellular phosphatidylinositol kinase inhibitors. The second induction medium includes basal medium and activin A at a working concentration of 80-150 ng / mL, and does not contain bone morphogenetic protein inhibitors or intracellular phosphatidylinositol kinase inhibitors. The third induction medium includes basal medium, A8301 at a working concentration of 0.5-1.5 μM, FGF2 at a working concentration of 7-20 ng / mL, BMP4 at a working concentration of 20-40 ng / mL, and TTPPB at a working concentration of 65-85 nM. The fourth induction medium includes basal medium, activator A at a working concentration of 5-15 ng / mL, BMP4 at a working concentration of 20-40 ng / mL, and hairy throat extract at a working concentration of 0.7-2 μM. The basal culture medium includes a mixed medium consisting of 50 vol% IMDM and 50 vol% Advanced F12, 0.8 vol%-1.2 vol% GlutaMAX, 0.8 vol%-1.2 vol% penicillin-streptomycin bispecific antibody, 0.8 vol%-1.2 vol% lipid concentrate with clearly defined chemical composition, and 1-thioglycerol, 0.5-0.9 μg / mL insulin, and 12-18 μg / mL transferrin at a final concentration of 400-500 μM. The induction medium is cultured for 20-28 hours, the induction medium is cultured for 20-28 hours, the induction medium is cultured for 20-28 hours, the induction medium is cultured for 20-28 hours, and the induction medium is cultured for 70-78 hours.

[0006] Preferably, the first induction medium includes basal medium, activin A at a working concentration of 100 ng / mL and CHIR99021 at a working concentration of 2 μM, and does not contain intracellular phosphatidylinositol kinase inhibitors. The second induction medium includes basal medium and activin A at a working concentration of 100 ng / mL, and does not contain bone morphogenetic protein inhibitors or intracellular phosphatidylinositol kinase inhibitors. The third induction medium includes basal medium, A8301 at a working concentration of 1 μM, FGF2 at a working concentration of 10 ng / mL, BMP4 at a working concentration of 30 ng / mL, and TTPPB at a working concentration of 75 nM. The fourth induction medium includes basal medium, activator A at a working concentration of 10 ng / mL, BMP4 at a working concentration of 30 ng / mL, and hairy throat extract at a working concentration of 1 μM.

[0007] Preferably, the basal culture medium comprises a mixed culture medium consisting of 50 vol% IMDM and 50 vol% Advanced F12, 1 vol% GlutaMAX, 1 vol% penicillin-streptomycin bispecific antibody, 1% lipid concentrate with clearly defined chemical composition, and 1-thioglycerol, 0.7 μg / mL insulin, and 15 μg / mL transferrin at a final concentration of 450 μM.

[0008] Preferably, the induction medium is cultured for 24 hours, the induction medium is cultured for 24 hours, the induction medium is cultured for 24 hours, the induction medium is cultured for 24 hours, and the induction medium is cultured for 72 hours.

[0009] Secondly, the present invention provides a combined induction culture medium using the following technical solution.

[0010] A combined induction medium includes a first induction medium, a second induction medium, a third induction medium, and a fourth induction medium; The first induction medium includes basal medium, activin A at a working concentration of 80-150 ng / mL and CHIR99021 at a working concentration of 1-3 μM, and does not contain intracellular phosphatidylinositol kinase inhibitors. The second induction medium includes basal medium and activin A at a working concentration of 80-150 ng / mL, and does not contain bone morphogenetic protein inhibitors or intracellular phosphatidylinositol kinase inhibitors. The third induction medium includes basal medium, A8301 at a working concentration of 0.5-1.5 μM, FGF2 at a working concentration of 7-20 ng / mL, BMP4 at a working concentration of 20-40 ng / mL, and TTPPB at a working concentration of 65-85 nM. The fourth induction medium includes basal medium, activator A at a working concentration of 5-15 ng / mL, BMP4 at a working concentration of 20-40 ng / mL, and hairy throat extract at a working concentration of 0.7-2 μM. The basal culture medium includes a mixed medium consisting of 50 vol% IMDM and 50 vol% Advanced F12, 0.8 vol%-1.2 vol% GlutaMAX, 0.8 vol%-1.2 vol% penicillin-streptomycin bispecific antibody, 0.8 vol%-1.2 vol% lipid concentrate with clearly defined chemical composition, and 1-thioglycerol at a final concentration of 400-500 μM, insulin at 0.5-0.9 μg / mL, and transferrin at 12-18 μg / mL.

[0011] Preferably, the first induction medium includes basal medium, activin A at a working concentration of 100 ng / mL and CHIR99021 at a working concentration of 2 μM, and does not contain intracellular phosphatidylinositol kinase inhibitors. The second induction medium includes basal medium and activin A at a working concentration of 100 ng / mL, and does not contain bone morphogenetic protein inhibitors or intracellular phosphatidylinositol kinase inhibitors. The third induction medium includes basal medium, A8301 at a working concentration of 1 μM, FGF2 at a working concentration of 10 ng / mL, BMP4 at a working concentration of 30 ng / mL, and TTPPB at a working concentration of 75 nM. The fourth induction medium includes basal medium, activator A at a working concentration of 10 ng / mL, BMP4 at a working concentration of 30 ng / mL, and hairy throat extract at a working concentration of 1 μM.

[0012] Preferably, the basal culture medium comprises a mixed culture medium consisting of 50 vol% IMDM and 50 vol% Advanced F12, 1 vol% GlutaMAX, 1 vol% penicillin-streptomycin bispecific antibody, 1% lipid concentrate with clearly defined chemical composition, and 1-thioglycerol, 0.7 μg / mL insulin, and 15 μg / mL transferrin at a final concentration of 450 μM.

[0013] Thirdly, the present invention provides a method for preparing hepatoblasts derived from the above-mentioned pluripotent stem cells or the application of the above-mentioned combined induction culture medium in the directed differentiation of hepatoblasts; The directed differentiation of hepatoblasts is not for disease diagnosis or treatment purposes.

[0014] In summary, the present invention has at least one of the following beneficial technical effects: This invention induces pluripotent stem cells to differentiate into hepatoblasts by using a four-stage induction medium instead of the traditional RIPM1640+B27 medium. This reduces culture costs while improving the cell viability of the resulting hepatoblasts, as well as increasing differentiation efficiency and the expression intensity and proportion of hepatoblast markers. Attached Figure Description

[0015] Figure 1 The images show bright-field comparisons of cell states on day 0, day 1, day 2, day 3, and day 6 of the preparation methods used in Example 1 and Comparative Examples 1-3 to induce iPSC differentiation. Figure 2 The images show a comparison of cell viability on the first, second, third, and sixth days after iPSC differentiation was induced using the preparation methods of Example 1 and Comparative Examples 1-3. Figure 3 This is an immunofluorescence comparison image of OTC4 on the second day after iPSC differentiation began, prepared using the methods of Example 1 and Comparative Examples 1-3. Figure 4 The image shows the immunofluorescence comparison of Nanog on the second day after iPSC differentiation began, using the preparation methods of Example 1 and Comparative Examples 1-3. Figure 5 The image shows a comparison of the immunofluorescence of FOXA2 cells on the second day after iPSC differentiation began, using the preparation methods of Example 1 and Comparative Examples 1-3. Figure 6 The image shows a comparison of the immunofluorescence of SOX17 cells on the second day after iPSC differentiation began, using the preparation methods of Example 1 and Comparative Examples 1-3. Figure 7 The image shows an immunofluorescence comparison of OTC4 cells on the second day after iPSC differentiation began, prepared using the methods described in Example 1, Comparative Example 2, and Comparative Example 4. Figure 8 The image shows the immunofluorescence comparison of Nanog on the second day after iPSC differentiation began, using the preparation methods of Example 1, Comparative Example 2, and Comparative Example 4. Figure 9 The image shows the immunofluorescence comparison of FOXA2 cells on the second day after iPSC differentiation began, prepared using the methods of Example 1, Comparative Example 2, and Comparative Example 4. Figure 10 The image shows the immunofluorescence comparison of SOX17 cells on the second day after iPSC differentiation began, prepared using the methods of Example 1, Comparative Example 2, and Comparative Example 4. Figure 11 This is a comparison of the immunofluorescence of AFP on the sixth day after the induction of iPSC differentiation using the preparation methods of Example 1 and Comparative Examples 1-3; Figure 12 The image shows a comparison of the immunofluorescence of HNF-4α on the sixth day after iPSC differentiation was induced using the preparation methods of Example 1 and Comparative Examples 1-3. Figure 13 This is a comparison of immunofluorescence images of EPCAM on day 6 after iPSC differentiation began, prepared using the methods of Example 1 and Comparative Examples 1-3. Figure 14 This is a comparison of the immunofluorescence of Ki67 cells on the sixth day after iPSC differentiation began, using the preparation methods of Example 1 and Comparative Examples 1-3. Figure 15 This is a comparison of immunofluorescence images of TBX3 on the sixth day after the induction of iPSC differentiation using the preparation methods of Example 1 and Comparative Examples 1-3; Figure 16 This is a comparison of the immunofluorescence of AFP on the sixth day after the induction of iPSC differentiation using the preparation methods of Example 1, Comparative Example 2, and Comparative Example 4. Figure 17 This is a comparison of the immunofluorescence of HNF-4α on the sixth day after the induction of iPSC differentiation using the preparation methods of Example 1, Comparative Example 2, and Comparative Example 4. Figure 18 This is an immunofluorescence comparison image of EPCAM on the sixth day after the induction of iPSC differentiation using the preparation methods of Example 1, Comparative Example 2, and Comparative Example 4. Figure 19 This is an immunofluorescence comparison image of Ki67 cells on the sixth day after iPSC differentiation began, prepared using the methods of Example 1, Comparative Example 2, and Comparative Example 4. Figure 20 This is an immunofluorescence comparison image of TBX3 on the sixth day after the induction of iPSC differentiation using the preparation methods of Example 1, Comparative Example 2, and Comparative Example 4. Figure 21 This is a comparison chart of the mRNA expression of OTC4, Nanog, FOXA2, and SOX17 on the second day after iPSC differentiation began using the preparation methods of Example 1 and Comparative Examples 1-3. Figure 22 This is a comparison chart of the mRNA expression of OTC4, Nanog, FOXA2 and SOX17 on the second day after iPSC differentiation began, using the preparation methods of Example 1, Comparative Example 2 and Comparative Example 4. Figure 23 This is a comparison chart of the mRNA expression of AFP, HNF-4α, EPCAM, Ki67 and TBX3 on the sixth day after iPSC differentiation was induced using the preparation methods of Example 1 and Comparative Examples 1-3. Figure 24This is a comparison chart of the mRNA expression of AFP, HNF-4α, EPCAM, Ki67 and TBX3 on the sixth day after iPSC differentiation was induced using the preparation methods of Example 1, Comparative Example 2 and Comparative Example 4. Figure 25 This is a comparison of the protein expression of OTC4, Nanog, FOXA2, and SOX17 on the second day after iPSC differentiation began using the preparation methods of Example 1 and Comparative Examples 1-3. Figure 26 This is a comparison chart of the protein expression of OTC4, Nanog, FOXA2 and SOX17 on the second day after iPSC differentiation began using the preparation methods of Example 1, Comparative Example 2 and Comparative Example 4. Figure 27 This is a comparison of the protein expression of AFP, HNF-4α, EPCAM, Ki67 and TBX3 on the sixth day after iPSC differentiation was induced using the preparation methods of Example 1 and Comparative Examples 1-3. Figure 28 This is a comparison of the protein expression of AFP, HNF-4α, EPCAM, Ki67, and TBX3 on the sixth day after iPSC differentiation was induced using the preparation methods of Example 1, Comparative Example 2, and Comparative Example 4. Detailed Implementation

[0016] The present invention will be further described in detail below with reference to the embodiments. The following embodiments are for illustrative purposes only and should not be considered as limiting the scope of the invention. Unless otherwise specified, specific conditions in the following embodiments were performed under conventional conditions or conditions recommended by the manufacturer. Unless otherwise specified, the methods used are conventional methods known in the art, and the consumables and reagents used are commercially available. Unless otherwise stated, the technical and scientific terms used herein have the same meaning as those familiar to those skilled in the art. Furthermore, any methods or materials similar to or equivalent to those described herein may also be applied to the present invention.

[0017] Example 1 Example 1 of this invention discloses a method for preparing hepatoblasts derived from pluripotent stem cells, the steps of which are as follows: Prepare approximately 1×10⁻⁶ hepatoblasts in a 6-well plate. 6 Approximately 5 × 10 cells per well, 12-well plate 5 Each cell per well, approximately 2.5 × 10⁶ cells per well, in a 12-well plate. 5Human induced pluripotent stem cells (iPSCs, DYR0100, purchased from the Shanghai Institute of Cell Biology) were evenly seeded into Matrigel-coated culture plates and cultured in mTeSR (STEMCELL, #85851) medium containing 10 μM ROCK inhibitor Y-27632 (Abmole, M1817). One day after seeding, when the cell confluence was approximately 80%-90%, differentiation was induced. Induction medium was prepared before differentiation began.

[0018] Preparation of basal culture medium: First, mix IMDM (gibco, C12440500BT) and Advanced F12 (gibco, 12634010) at a volume ratio of 1:1 to obtain a mixed culture medium. Then, based on the mixed culture medium, add 1 vol% GlutaMAX (gibco, 35050061), 1 vol% penicillin-streptomycin (gibco, 15070063), 1 vol% lipid concentrate with a clearly defined chemical composition (procell, PB180643), 1-thioglycerol (Maclean, M6145), and control the final concentration of the active ingredient to 450 μM. Add insulin (Maclean, R917753) and control the final concentration of the active ingredient to 0.7 μg / mL. Add transferrin (Sigma, T1147) and control the final concentration of the active ingredient to 15 μg / mL.

[0019] First induction medium: Add 100 ng / mL activin A (MCE, HY-P70311) and 2 μM glycogen synthase kinase inhibitor (CHIR99021; MCE, HY-10182) to the basal medium.

[0020] Second induction medium: Add 100 ng / mL of activator A to the basal medium.

[0021] Third induction medium: 1 μM of TGF-β type I receptor inhibitor (A8301; MCE, HY-10432), 10 ng / mL of FGF signaling pathway activator (FGF2; MCE, HY-P7004), 30 ng / mL of BMP signaling pathway activator (BMP4; MCE, HY-P7007), and 75 nM of retinoic acid activator (TTNPB; MCE, HY-15682) were added to the basal medium.

[0022] Fourth induction medium: Add 10 ng / mL activator A, 30 ng / mL BMP signaling pathway activator (BMP4), and 1 μM cAMP / PKA activator (Forskolin; MCE, HY-15371) to the basal medium.

[0023] At the start of induction differentiation, mTeSR medium was removed and replaced with the first induction medium for 24 h to obtain protoblast cells; protoblast cells were cultured in the second induction medium for 24 h to obtain shaped endoderm cells; shaped endoderm cells were cultured in the third induction medium for 24 h to obtain hindforegut cells; and hindforegut cells were cultured in the fourth induction medium for 72 h to obtain hepatocytes.

[0024] Comparative Example 1 Comparative Example 1 discloses a method for preparing hepatoblasts derived from pluripotent stem cells. The difference between Comparative Example 1 and Example 1 is that the basal medium in the first induction medium, the second induction medium, the third induction medium and the fourth induction medium in Comparative Example 1 are all replaced with RIPM1640 medium (gibco, 31800089) plus 1% (V / V) B27 (gibco, 17504044).

[0025] Comparative Example 2 Comparative Example 2 discloses a method for preparing hepatoblasts derived from pluripotent stem cells. The difference between Comparative Example 2 and Example 1 is that 50 nM of an intracellular phosphatidylinositol kinase inhibitor (PI103; MCE, HY-10115) is added to the first induction medium in Comparative Example 2; and 250 nM of a bone morphogenetic protein inhibitor (DM3189; MCE, HY-12071) and 50 nM of an intracellular phosphatidylinositol kinase inhibitor (PI103) are added to the second induction medium.

[0026] Comparative Example 3 Comparative Example 3 discloses a method for preparing hepatoblasts derived from pluripotent stem cells. The difference between Comparative Example 3 and Comparative Example 2 is that the basal medium in the first induction medium, the second induction medium, the third induction medium and the fourth induction medium in Comparative Example 3 are all replaced with RIPM1640 medium (gibco, 31800089) plus 1% (V / V) B27 (gibco, 17504044).

[0027] Comparative Example 4 Comparative Example 4 discloses a method for preparing hepatoblasts derived from pluripotent stem cells. The difference between Comparative Example 4 and Example 1 is that the third induction medium in Comparative Example 4 is replaced with a basal medium containing 20 ng / mL KGF (MCE, HY-P70597) and 5 µM SB431542 (MCE, HY-10431), and the fourth induction medium is replaced with a basal medium containing 20 ng / mL KGF, 20 ng / mL BMP4, 10 ng / mL BMP2 (MCE, HY-P7006), and 10 ng / mL bFGF (MCE, HY-P7004).

[0028] Testing and Inspection (1) Bright-field images of cell states on day 0 (labeled as iPSC), day 1 (labeled as APS), day 2 (labeled as DE), day 3 (labeled as PFG), and day 6 (labeled as HB) of iPSCs induced by the preparation methods of Example 1 and Comparative Examples 1-3 were obtained. The results are as follows: Figure 1 As shown.

[0029] (2) On the first day (labeled APS), the second day (labeled DE), the third day (labeled PFG), and the sixth day (labeled HB) of iPSC differentiation induced by the preparation methods of Example 1 and Comparative Examples 1-3, cell viability was detected using the CCK-8 assay kit according to the kit instructions. Three replicates were set up for each stage. The results are as follows: Figure 2 As shown.

[0030] (3) On the second day after iPSC differentiation began using the preparation methods of Example 1 and Comparative Examples 1-4 (labeled DE), the immunofluorescence of OTC4, Nanog, FOXA2, and SOX17 was detected. The steps were as follows: the culture medium was aspirated, the cells were washed once with PBS, then fixed with 4% paraformaldehyde at room temperature for 20 minutes, washed three times with PBS, permeabilized with 0.5% Triton X-100 for 20 minutes, washed three times with PBS, and then blocked with goat serum for 30 minutes; then the diluted primary antibody solution was added, and the cells were incubated overnight at 4 degrees Celsius; the primary antibody was recovered the next day, the cells were washed twice with PBS, the diluted fluorescent secondary antibody was added, and the cells were incubated at room temperature for 1 hour; after washing three times with PBS, the cell nuclei were stained with DAPI for 5 minutes, then washed with PBS, and an anti-fluorescence quencher was added. The cells were observed and photographed under a fluorescence microscope. The comparative results of Example 1 and Comparative Examples 1-3 are as follows. Figure 3-6 As shown, the comparison results of Example 1, Comparative Example 2, and Comparative Example 4 are as follows: Figure 7-10As shown. On the sixth day (labeled HB) after induction of iPSC differentiation using the preparation methods of Example 1 and Comparative Examples 1-4, the immunofluorescence of AFP, HNF-4α, EPCAM, Ki67, and TBX3 was detected using the same method. The comparative results of Example 1 and Comparative Examples 1-3 are shown in the figure below. Figure 11-15 As shown, the comparison results of Example 1, Comparative Example 2, and Comparative Example 4 are as follows: Figure 16-20 As shown in Table 1 below, the primary antibody information used in the above process is as follows.

[0031] Table 1:

[0032] (4) On the second day after iPSC differentiation began using the preparation methods of Example 1 and Comparative Examples 1-4 (labeled DE), the mRNA expression of OTC4, Nanog, FOXA2, and SOX17 was detected. The steps were as follows: RNA was extracted from cells in each group according to the SteadyPure RNA Extraction Kit (Aikerui Biotechnology, AG21024). 800 ng of RNA samples were reverse transcribed into cDNA using a reverse transcription kit. The obtained cDNA was further diluted 5-fold and then subjected to qPCR. Each sample was tested in triplicate. The comparison results of Example 1 and Comparative Examples 1-3 are as follows: Figure 21 As shown, the comparison results of Example 1, Comparative Example 2, and Comparative Example 4 are as follows: Figure 22 As shown. On the sixth day (labeled HB) after induction of iPSC differentiation using the preparation methods of Example 1 and Comparative Examples 1-4, the mRNA expression of AFP, HNF-4α, EPCAM, Ki67, and TBX3 was detected using the same method. The comparison results of Example 1 and Comparative Examples 1-3 are shown below. Figure 23 As shown, the comparison results of Example 1, Comparative Example 2, and Comparative Example 4 are as follows: Figure 24 As shown.

[0033] (5) On the second day after iPSC differentiation began using the preparation methods of Example 1 and Comparative Examples 1-4 (marked as DE), the protein expression of OTC4, Nanog, FOXA2, and SOX17 was detected. The steps were as follows: Sample preparation: The supernatant was removed, and the cells were washed once with 1×PBS. The supernatant was removed. An appropriate amount of RIPA tissue / cell lysis buffer (containing PMSF) was added according to the actual situation. The cells were scraped off with a cell scraper, and the cell suspension was transferred to a 2mL centrifuge tube. The cells were lysed on ice using an ultrasonic homogenizer and centrifuged at 14000g for 10 minutes at 4℃. The supernatant after centrifugation was transferred to a 1.5mL centrifuge tube. The protein concentration of the samples was detected using a BCA protein concentration assay kit. The samples were diluted to the same concentration using RIPA tissue / cell lysis buffer (containing PMSF) according to the measured protein concentration. 5× protein loading buffer was added, mixed, and placed in hot water at 100℃ for 5 minutes. The samples were then stored at -80℃ for later use. Western Blot Procedure: SDS-PAGE Protein Electrophoresis: Place the prepared protein gel into the electrophoresis tank and pour in the SDS-PAGE running buffer; remove the comb and add the protein sample and three-color pre-stained protein marker to each well. The electrophoresis voltage is 90V→120V; Transfer: Cut the required portion of the protein gel for transfer. The transfer voltage is 100V. Adjust the transfer time according to the protein size; Blocking: Block with 1×TBST solution containing 5% skim milk powder at room temperature for more than 1 hour; Primary Antibody Incubation: Aspirate the waste liquid and add 5mL of the corresponding primary antibody diluted with TBST solution containing 5% skim milk powder. Incubate overnight at 4℃; then wash three times with 1×TBST, 10 minutes each time; secondary antibody incubation: add 3 mL of HRP-labeled goat anti-rabbit IgG (H+L) diluted with TBST (Beyotime, A0208, 1:5000 dilution), incubate at room temperature for 1 hour, then wash three times with 1×TBST, 10 minutes each time; development: mix HRP substrate peroxide solution and HRP substrate luminol reagent in the developing solution at a 1:1 ratio, drop an appropriate amount onto the membrane, incubate in a dark room for about 1 minute, and then develop in a high-sensitivity multifunctional imaging system. The comparative results of Example 1 and Comparative Examples 1-3 are as follows. Figure 25 As shown, the comparison results of Example 1, Comparative Example 2, and Comparative Example 4 are as follows: Figure 26 As shown. On the sixth day (labeled HB) after induction of iPSC differentiation using the preparation methods of Example 1 and Comparative Examples 1-4, the protein expression of AFP, HNF-4α, EPCAM, Ki67, and TBX3 was detected using the same method. The comparison results of Example 1 and Comparative Examples 1-3 are shown below. Figure 27 As shown, the comparison results of Example 1, Comparative Example 2, and Comparative Example 4 are as follows: Figure 28 As shown.

[0034] Results Analysis Reference Figure 1 and Figure 2 , Figure 1 The results showed that when using the preparation method of Example 1, the morphology and number of cells were significantly better than those of cells prepared using the preparation method of Comparative Example 1, starting from the APS stage. This indicates that the first induction medium, the second induction medium, the third induction medium and the fourth induction medium of the present invention are beneficial to improving the viability of each cell during the induction process. Figure 2 The results showed that when iPSC differentiation was induced using the preparation methods of Example 1 and Comparative Example 2, the cell viability at each stage was significantly better than that induced using the preparation methods of Comparative Example 1 and Comparative Example 3. This indicates that the use of basal culture medium is beneficial to improving cell viability at each stage of iPSC differentiation induction. Figure 1 The results presented are consistent.

[0035] Reference Figure 3-28The results of the HB phase showed that the protein levels (immunofluorescence intensity and immunoblot band intensity) and mRNA expression levels of hepatoblast markers AFP, EPCAM, and HNF-4α in hepatoblast cells prepared using the preparation method of Example 1 were higher than those in cells prepared using the methods of Comparative Examples 1-4. This indicates that treating iPSCs with the preparation method of Example 1 is beneficial for activating the hepatic differentiation pathway, enhancing the activity and differentiation efficiency of hepatoblast cells, and increasing the expression of hepatoblast markers in the prepared hepatoblast cells. Referring to the results of the DE stage, it can be found that the cells cultured using the preparation method of Comparative Example 2 showed the strongest expression of DE markers (FOXA2 / SOX17) in the DE stage, indicating that the preparation method of Comparative Example 2 can most effectively drive the cells to transform into the fixed endoderm. However, the hepatocyte markers of the cells that finally reached the HB stage were lower than those of the hepatocytes prepared using the preparation method of Example 1. This indicates that the hepatic differentiation potential of the DE stage cells cultured using the preparation method of Comparative Example 2 is insufficient. The high expression of FOXA2 / SOX17 may only be "broad-spectrum endoderm induction" and has not truly activated the key pathway for liver differentiation. On the other hand, the DE stage cells cultured using the preparation method of Example 1 have stronger intrinsic hepatic differentiation potential and are more suitable "seed cells" for liver differentiation. That is, compared with the preparation method of Comparative Example 2, the preparation method of Example 1, by removing the intracellular phosphatidylinositol kinase inhibitor and bone morphogenetic protein inhibitor from the composition of the first and second induction media, is more conducive to improving the hepatic differentiation potential of the cultured DE stage cells and increasing the expression intensity and proportion of hepatocyte markers in hepatocytes, achieving unexpected technical effects. For seed cells used in subsequent bioengineering of liver cells, a high proportion of hepatocytes means no additional purification is needed, reducing production costs. When the differentiation purity reaches over 90%, they can be directly used for subsequent applications without expensive purification steps such as flow cytometry. This significantly reduces the complexity and cost of GMP-level cell production. Furthermore, it ensures therapeutic safety and reduces the risk of non-target cells. Low-purity differentiation products may contain undifferentiated pluripotent stem cells (with tumorigenic risk) or other non-hepatic lineage cells. A high proportion of hepatocytes minimizes these risks, meeting the safety requirements of clinical-grade cell therapy products. For drug testing, it improves predictive accuracy and reduces false negatives / false positives. A high proportion of hepatocytes, after subsequent liver-like induction, yields a cell population that more closely resembles the physiological state of hepatocytes in vivo, more accurately reflecting the metabolic and toxic processes of drugs. Liver function cells obtained from high-purity hepatocytes after liver-like cell induction respond earlier and more sensitively to hepatotoxic drugs (such as acetaminophen and diclofenac), with toxic reactions detectable at lower concentrations and shorter exposure times. When the differentiation system is stable and has high purity, specific genotype hepatocyte models can be constructed based on patient-derived iPSCs to assess individualized differences in drug metabolism and toxicity risks.Referring to the results of culturing iPSCs using the preparation methods of Example 1, Comparative Example 2, and Comparative Example 4, it can be found that when the inducing components in the third and fourth induction media were changed in the culture method of Comparative Example 4, the hepatocyte markers of the obtained HB stage cells also decreased significantly. This indicates that the intrinsic hepatic differentiation potential of DE stage cells induced by the preparation method of Example 1 needs to be effectively activated in conjunction with the third and fourth induction media.

[0036] The above are all optional embodiments of the present invention and are not intended to limit the scope of protection of the present invention. Therefore, all equivalent changes made in accordance with the structure, shape and principle of the present invention should be covered within the scope of protection of the present invention.

Claims

1. A method for preparing hepatoblasts derived from pluripotent stem cells, characterized in that: Includes the following steps: Pluripotent stem cells were cultured sequentially in the first induction medium, the second induction medium, the third induction medium, and the fourth induction medium to obtain hepatoblasts; The first induction medium includes basal medium, activin A at a working concentration of 80-150 ng / mL and CHIR99021 at a working concentration of 1-3 μM, and does not contain intracellular phosphatidylinositol kinase inhibitors. The second induction medium includes basal medium and activin A at a working concentration of 80-150 ng / mL, and does not contain bone morphogenetic protein inhibitors or intracellular phosphatidylinositol kinase inhibitors. The third induction medium includes basal medium, A8301 at a working concentration of 0.5-1.5 μM, FGF2 at a working concentration of 7-20 ng / mL, BMP4 at a working concentration of 20-40 ng / mL, and TTPPB at a working concentration of 65-85 nM. The fourth induction medium includes basal medium, activator A at a working concentration of 5-15 ng / mL, BMP4 at a working concentration of 20-40 ng / mL, and hairy throat extract at a working concentration of 0.7-2 μM. The basal culture medium includes a mixed medium consisting of 50 vol% IMDM and 50 vol% Advanced F12, 0.8 vol%-1.2 vol% GlutaMAX, 0.8 vol%-1.2 vol% penicillin-streptomycin bispecific antibody, 0.8 vol%-1.2 vol% lipid concentrate with clearly defined chemical composition, and 1-thioglycerol, 0.5-0.9 μg / mL insulin, and 12-18 μg / mL transferrin at a final concentration of 400-500 μM. The induction medium is cultured for 20-28 hours, the induction medium is cultured for 20-28 hours, the induction medium is cultured for 20-28 hours, the induction medium is cultured for 20-28 hours, and the induction medium is cultured for 70-78 hours.

2. The method for preparing hepatoblasts derived from pluripotent stem cells according to claim 1, characterized in that: The first induction medium includes basal medium, activin A at a working concentration of 100 ng / mL and CHIR99021 at a working concentration of 2 μM, and does not contain intracellular phosphatidylinositol kinase inhibitors. The second induction medium includes basal medium and activin A at a working concentration of 100 ng / mL, and does not contain bone morphogenetic protein inhibitors or intracellular phosphatidylinositol kinase inhibitors. The third induction medium includes basal medium, A8301 at a working concentration of 1 μM, FGF2 at a working concentration of 10 ng / mL, BMP4 at a working concentration of 30 ng / mL, and TTPPB at a working concentration of 75 nM. The fourth induction medium includes basal medium, activator A at a working concentration of 10 ng / mL, BMP4 at a working concentration of 30 ng / mL, and hairy throat extract at a working concentration of 1 μM.

3. The method for preparing hepatoblasts derived from pluripotent stem cells according to claim 1, characterized in that: The basal culture medium includes a mixed medium consisting of 50 vol% IMDM and 50 vol% Advanced F12, 1 vol% GlutaMAX, 1 vol% penicillin-streptomycin bispecific antibody, 1% lipid concentrate with clearly defined chemical composition, and 1-thioglycerol, 0.7 μg / mL insulin, and 15 μg / mL transferrin at a final concentration of 450 μM.

4. The method for preparing hepatoblasts derived from pluripotent stem cells according to claim 1, characterized in that: The induction medium is cultured for 24 hours, the induction medium is cultured for 24 hours, the induction medium is cultured for 24 hours, the induction medium is cultured for 24 hours, and the induction medium is cultured for 72 hours.

5. A combined induction culture medium, characterized in that: It includes a first induction medium, a second induction medium, a third induction medium, and a fourth induction medium; The first induction medium includes basal medium, activin A at a working concentration of 80-150 ng / mL and CHIR99021 at a working concentration of 1-3 μM, and does not contain intracellular phosphatidylinositol kinase inhibitors. The second induction medium includes basal medium and activin A at a working concentration of 80-150 ng / mL, and does not contain bone morphogenetic protein inhibitors or intracellular phosphatidylinositol kinase inhibitors. The third induction medium includes basal medium, A8301 at a working concentration of 0.5-1.5 μM, FGF2 at a working concentration of 7-20 ng / mL, BMP4 at a working concentration of 20-40 ng / mL, and TTPPB at a working concentration of 65-85 nM. The fourth induction medium includes basal medium, activator A at a working concentration of 5-15 ng / mL, BMP4 at a working concentration of 20-40 ng / mL, and hairy throat extract at a working concentration of 0.7-2 μM. The basal culture medium includes a mixed medium consisting of 50 vol% IMDM and 50 vol% Advanced F12, 0.8 vol%-1.2 vol% GlutaMAX, 0.8 vol%-1.2 vol% penicillin-streptomycin bispecific antibody, 0.8 vol%-1.2 vol% lipid concentrate with clearly defined chemical composition, and 1-thioglycerol at a final concentration of 400-500 μM, insulin at 0.5-0.9 μg / mL, and transferrin at 12-18 μg / mL.

6. The combined induction culture medium according to claim 5, characterized in that: The first induction medium includes basal medium, activin A at a working concentration of 10 ng / mL and CHIR99021 at a working concentration of 2 μM, and does not contain intracellular phosphatidylinositol kinase inhibitors. The second induction medium includes basal medium and activin A at a working concentration of 100 ng / mL, and does not contain bone morphogenetic protein inhibitors or intracellular phosphatidylinositol kinase inhibitors. The third induction medium includes basal medium, A8301 at a working concentration of 1 μM, FGF2 at a working concentration of 10 ng / mL, BMP4 at a working concentration of 30 ng / mL, and TTPPB at a working concentration of 75 nM. The fourth induction medium includes basal medium, activator A at a working concentration of 100 ng / mL, BMP4 at a working concentration of 30 ng / mL, and salivain at a working concentration of 1 μM.

7. The combined induction culture medium according to claim 5, characterized in that: The basal culture medium consists of a mixed medium of 50 vol% IMDM and 50 vol% Advanced F12, 1 vol% GlutaMAX, 1 vol% penicillin-streptomycin bispecific antibody, 1% lipid concentrate with clearly defined chemical composition, and 1-thioglycerol, 0.7 μg / mL insulin, and 15 μg / mL transferrin at a final concentration of 450 μM.

8. The application of a preparation method according to any one of claims 1-4 or a combined induction culture medium according to claims 5-7 in the directed differentiation of hepatocytes; The directed differentiation of hepatoblasts is not for disease diagnosis or treatment purposes.